Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.47 |
| ▸ | HTR1A | P08908 | 14/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541626 | 0.90 | MAPK14 (0.52) | SLC6A2SLC6A4SLC6A3HTR1AMAPK14 | |
| SCHEMBL3538396 | 0.89 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3HTR1AMAPK14 | |
| SCHEMBL3547741 | 0.86 | HTR2C (0.51) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| SCHEMBL3548607 | 0.86 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| Bromide SCHEMBL3540320 | 0.85 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3HTR1AMAPK14 | |
| SCHEMBL3544128 | 0.84 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3HTR1AMAPK14 | |
| SCHEMBL3544124 | 0.84 | HTR2C (0.56) | SLC6A2SLC6A4SLC6A3HTR1AHTR6 | |
| SCHEMBL3547561 | 0.84 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3HTR1AMAPK14 | |
| SCHEMBL3542802 | 0.84 | MAPK14 (0.45) | SLC6A2SLC6A4SLC6A3HTR1AMAPK14 | |
| SCHEMBL3547302 | 0.84 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR1AMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | H.LUNDBECK A/S (DK) | 2006-05-11 | — | — | US | claimed |
| US-7732463-B2 | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2010-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100242-A1 | such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders | HTR4, HTR5A, TPH1 | SLC6A2 84/4885SLC6A4 14/4885SLC6A3 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.